Objective: The aim of this study was to detail the clinical efficacy of low-level laser therapy (LLLT) for the management of bisphosphonate-induced osteonecrosis of the jaws (ONJ-BP). Background: ONJ-BP is the correct term, recently emerged, to describe a significant complication in a subset of patients receiving drugs such as zoledronic acid, pamidronate, and alendronate. No definitive standard of care has been set for ONJ-BP and no definitively agreed guidelines have been provided. There is currently no consensus on the correct approach to the issue. Materials and Methods: The investigators studied a prospective cohort of 20 patients affected by ONJ-BP, who received biostimulation with a pulsed diode laser (GaAs). Patients were exposed to a 904-nm infrared laser (50 kHz, 28.4 J=cm 2 energy density, 40% duty cycle, spot size 0.8 cm). Outcome variables were the size of lesions, edema, visual analogue score of pain, presence of pus, fistulas, and halitosis. Preoperative results were compared with the postoperative outcome and statistically evaluated. Results: Four weeks after LLLT, a statistically significant difference was observed for reported pain ( p ¼ 0.0001), clinical size ( p ¼ 0.0034), edema ( p ¼ 0.0005), and presence of pus and fistulas ( p ¼ 0.0078 and p ¼ 0.03, respectively). Conclusion: This study suggests that LLLT would appear to be a promising modality of treatment for patients with ONJ-BP, providing that clinical efficacy is safe and well tolerated, especially by those patients who require conservative treatment. Of course, this needs to be addressed further in larger and randomly controlled studies in different clinical settings.
Introduction
L ow-level laser therapy (LLLT) is an innovative approach, increasingly used in medicine, which has been shown to have several different effects, including pain relief, wound healing, and nerve regeneration. It has potential antimicrobial and biostimulating effects when applied to oral tissues by improving wound healing, 1,2 enhancing epithelization after periodontal surgery, 3, 4 minimizing oedema after third molar surgery, 5 and preventing induced oral mucositis. 6 It has been proven that LLLT stimulates the proliferation of cells 7 and the formation of new lymphatic and blood vessels. 8 Bisphosphonate-induced osteonecrosis of the jaws (ONJ-BP) is the correct term, recently emerged, to describe a significant complication in a subset of patients receiving a class of agents used to treat osteoporosis and malignant bone metastases. [9] [10] [11] The main pathogenesis of ONJ-BP still remains to be completely elucidated; apparently, the ability of bisphosphonates to inhibit vascular endothelial growth factor and formation of new capillaries may be accentuated in the jaw bones with high vascularity and bone turnover. 12 It has been reported that LLLT can improve bone mineralization. [13] [14] [15] The effect of LLLT on bone regeneration has been the focus of more recent research, including within dentistry. Studies have investigated the ability of low-level laser irradiation to stimulate both bone production and boneimplant interaction.
14 For these reasons, it can be postulated that laser biostimulation may be helpful in treating ONJ-BP. 16 The aim of this study was to estimate the effects and the efficacy of LLLT on the outcome of ONJ-BP. 
Materials and Methods

Study sample and inclusion criteria
Consecutive cases of exposed bone in the mandible or maxilla after treatment with bisphosphonates (BPs) were prospectively included in this dataset. In accordance with published recommendations, ONJ-BP was diagnosed using a two-step approach consisting of clinical identification of exposed bone in the maxillofacial area, occurring spontaneously or in association with dental surgery, without evidence of healing, and excluding lesions derived from metastatic jaw disease or resulting from radiotherapy. At the time of the diagnosis, a computerised clinical file was created for the patient, which recorded information on age, gender, presence of any systemic disease, and use of any drugs. In particular, each patient was asked for a detailed history concerning the use, dose, frequency, and the duration of therapy with BPs. Patients who had been treated with zoledronic acid (ZOL) received 4 mg intravenously for 15 min monthly; those treated with pamidronate (PAM) received 90 mg for 1 h intravenously over the same period; and those with alendronate (ALE) received 70 mg weekly orally.
All patients were clinically evaluated by a skilled group of oral health care providers, who recorded the clinical aspect of the lesions, size and sites of oral involvement, as well as signs of secondary infection.
The extent of ONJ-BP was staged according to previous published classification: 18 stage I -exposed=necrotic bone in patients who are asymptomatic, <1 cm (stage IA) and >1 cm (stage IB); stage II -exposed=necrotic bone in patients with pain, <2 cm (stage IIA) and >2 cm (stage IIB); stage IIImultiple lesions (stage IIIA) and multiple lesions with one or more of pathologic fracture, extra-oral fistulas, or osteolysis extending to the inferior border of the mandible (stage IIIB). Nevertheless, lesions larger than 2.5 cm were excluded from the present study.
The local ethical committee approved the study protocol. All patients were informed of the nature of the experimental procedures and consent was obtained.
Laser procedure
A Lumix 2 HFPL Dental Device ( Fisioline S.r.l.,Verduno, Cuneo,Italy) was used. The Lumix 2 is a desktop laser instrument with a pulsed diode that provides peak powers of up to 40 W for very effective photonic tissue penetration. The power is modulated so that it is adjustable from 10 to 100%. This allows the average power to be matched to the specific needs of the patient and achieves high-depth tissue penetration while providing gentle average power levels. The laser beam is transmitted through fiber-optic cables and is guided by a red LED light (with an output power of 7 mW, which represents less than 4% of the whole power of the infrared) at the treatment probe aperture to ensure patient comfort and treatment accuracy.
Each patient underwent 10 laser irradiation sessions over a period of 20 days: four sessions in the first week of treatment, three sessions in the second week, and another three in the last week. Patients were exposed to a pulsed 904-nm infrared laser (50 kHz, 28.4 J=cm 2 energy density, 40% duty cycle, spot size 0.8 cm). According to the manufacturer's instructions, in each session the laser was used in slight contact with the tissues for 15 min: 59 J at 60 kHz for 5 min, and 120 J at 40 kHz for 10 min.
Clinical assessments
A single skilled examiner (L.R.) recorded the size of lesion, edema, and pain; moreover, presence of pus, fistulas, and halitosis were also detailed. Clinical measurements were performed 1 h before the laser procedure (T0) and 28 days after (T1). Facial edema was evaluated by measuring the distance from the corner of the mouth to the attachment of the ear lobe following the bulge of the cheek, and the distance from the outer canthus of the eye to the angle of the mandible.
Severity of patient pain perception was assessed using a Visual Analogue Scale (VAS). The VAS consisted of a 10-cm horizontal line marked 0 ( ¼ no pain) to 10 ( ¼ most severe pain experienced). Patients were requested to mark the scale at each visit. Complete resolution of the symptoms (no symptoms) was defined as the absence of any discomfort, corresponding to a zero VAS score. Partial response, worsening, or persistence of the patient's condition meant a decrease, increase, or no change at all in the patient's score. The difference between baseline and endpoint scores numerically expresses the clinical and symptomatic improvement.
At T1, the evolution of the disease was detailed as follows: resolution of symptoms (RS) -no pain or symptoms of infections; clinical achievement (CA) -complete or partial covering of the previously exposed bone with re-epithelization, with no signs of oral or cutaneous draining fistulas; failure (FA) -progressive exposure of necrotic bone or additional complication (e.g., fracture).
The typical follow-up schedule was 1, 2, 3, 6, 9, and 12 mo postoperatively in the first year, followed by every 3 mo thereafter.
Statistical analysis
Describing general information, data were reported as means AE standard deviation, unless otherwise described. Wilcoxon's signed rank test was used to calculate the significance of the outcome data at T1. The results were statistically compared using the Fisher's exact test for qualitative variables and the Mann-Whitney U test for the quantitative data. P values of 0.05 were considered to be statistically significant. SPSS (SPSS for Windows, version 11, SPSS Inc., Chicago, IL) statistical software was utilized.
Results
Overall baseline clinical characteristics of the study population are reported in Table 1 . The mean duration of followup was 242 days (AE38). A total of 20 patients took part in the study, of which 14 were women (70%). The mean age at presentation was 71.3 years (AE9.86). Patients were treated with BPs for a mean of 42.95 mo (AE32.16) at the time of diagnosis. Usually, in our experience, the continuation of BPs treatment after ONJ diagnosis was left to the discretion of the treating physicians. However, in this series, no patients discontinued BPs. We also examined patient pain perception after each procedure, and the VAS score was 0 in all cases.
Differences in the reported parameters between T0 and T1 are detailed in Table 2 ( Figs. 1 and 2) . A statistically significant difference was observed for reported pain, clinical size, edema, and presence of pus and fistulas. No reported complications or therapy side effects were observed in any of the patients treated. Table 1 reported the clinical stage at T0. At T1, four patients were classified as stage 0, thre as stage IA, four as stage IB, and nine as stage IIA. Eight patients (40%) remained stable between T0 and T1, whereas 12 patients (60%) improved with RS and CA. The results of staging before and after the treatment are shown in Fig. 3 . No variables were found to be significant predictors of the outcome of ONJ-BP lesions, even for patients on i.v. BPs (especially those on ZOL). Those who also underwent chemotherapy treatment seemed to have a worse prognosis (data not shown).
After T1, patients were followed up every 8 mo on average. Symptoms remained stable in 17 patients and the size of lesions remained stable in 16 patients. Two patients had FA, developing progressive exposure of necrotic bone, with no pain reported for one case (50%). During the follow-up period, three patients developed new lesions with pus, two patients had new fistulas, and two patients reported halitosis again.
Discussion
To date, no definitive standard of care has been set for ONJ-BP and no definitively agreed guidelines have been provided. There is no consensus on the surgical or nonsurgical approach to the issue. Moreover, at present, there is little prospective literature on the long-term management and outcome of ONJ-BP patients. For most patients, a complete cure is not possible. However, a complete resolution of 
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symptoms and partial clinical achievement should at least be one of the primary goals in the management of ONJ-BP. Numerous clinical protocols to treat areas of exposed bone have been proposed, reporting reductions or even resolutions of clinical signs using conservative treatment. However, extensive and radical surgical resections have rarely resulted in long-term successful wound closure and have sometimes led to worsening of the diseases. [18] [19] [20] [21] Controversies about tissues biostimulating with LLLT still remain; a lack of homogeneous reporting of physical and biological variables makes the summing up of the results particularly complicated. 22 In vitro phototherapy seemed to influence cell growth and protein production, and it has possibly been shown to act as a proliferative stimulus on osteoblast-like cells. 23, 24 The use of LLLT in ONJ-BP has been reported recently, 16 showing complete clinical success or improvements in more than 80% of cases, in contrast to previous retrospective studies analyzing conservative treatment. This study was designed as a prospective investigation to detail the effectiveness of laser therapy in managing oral necrotic lesions.
In recent years, laser technology has been used to improve the clinical results of bone surgeries and to promote a more comfortable postoperative period and quicker healing. For this reason, LLLT could be taken as a possible choice in the management of bone lesions in ONJ-BP-positive patients.
The general population characteristics of the presented cohort are comparable to those previously reported. Our results showed that the use of LLLT in the management of ONJ-BP has a significant effect on reducing pain and clinical parameter of inflammation. Our findings might have a significant clinical impact, since LLLT is easy to perform, does not increase morbidity, or present side effects. Obtained results were also stable during the follow-up period. According to the manufacturer's instructions, two protocols of irradiation have been used, the lower with an antimicrobial effect, the other with a biostimulating effect. Whilst healing was the first aim of the study, another purpose was controlling inflammation around involved tissues by possibly decreasing infection.
We decided to exclude lesions larger than 2.5 cm because, in our experience, these patients typically have pain that impacts the quality of life, and surgical debridement, even if it is not completely resolvable, may offer long-term palliation with resolution of acute infection and pain. 25 The reduction of the necrotic lesions obtained at T1 is, however, imputable to the re-epithelization of the superficial mucosa more than to a real improvement of the deep bony lesion. Similar to these findings, recent studies have further focused on laser impact on cell-growth processes involved in wound repair. 26 We reported that use of chemotherapy reduced the healing rate, even if in a non-statistical matter, and this is similar to recent findings. 27 Moreover, it is always important to keep in mind that many of these patients have a compromised systemic condition, usually not compatible with more radical treatments, and a low expectation of life. For this reason, obtaining a reasonable quality of life can be considered as the most favourable goal, remembering that the standard objective for controlling ONJ-BP should always be prevention. 28, 29 In our series, for example, pain score showed a statistically significant improvement, and patients reported a great enhancement in quality of life. LLLT has been shown to promote an increase in the synthesis and release of endorphins, with reduced sensory nerve conduction. 
Conclusion
This study suggests that LLLT currently appears to be a possible treatment for patients with ONJ-BP. It significantly improved symptoms, even for those patients with bone exposure still visible. In many cases, LLLT decreased the size of lesions safely and was well tolerated, especially in those patients who required conservative treatment. Whilst these results are not conclusive and are more of a step forward in the enhanced management of this rare condition, it would be very interesting to know if this statement would be the same with a greater number of patients.
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